THMO - ThermoGenesis Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ThermoGenesis Holdings, Inc.

2711 Citrus Road
Rancho Cordova, CA 95742
United States
916-858-5100
http://www.thermogenesis.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees53

Key Executives

NameTitlePayExercisedYear Born
Dr. Xiaochun Xu M.B.A., Ph.D.Chairman, CEO & Pres460kN/A1971
Mr. Jeff CaubleCFO, Principal Financial & Accounting Officer and Sec.160kN/A1973
Mr. Philip H. CoelhoChief Technology OfficerN/AN/A1944
Ms. Haihong ZhuPres of ThermoGenesisN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company operates through two segments, Device and Clinical Development. It manufactures and markets products for clinical bio-banking applications, including AXP Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company also offers PXP Point-of-Care System, an automated sterile system that allows for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification using the company's proprietary buoyance-activated cell sorting (BACS) technology. In addition, it provides manual processing sets comprising transfer/freezing bag sets, freezing bags, and cell wash/infusion bag sets. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

Corporate Governance

ThermoGenesis Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.